Kadmon (NYSE:KDMN) had its price objective upped by equities researchers at Jefferies Group to $16.00 in a report released on Tuesday, February 13th. The brokerage presently has a “buy” rating on the stock. Jefferies Group’s target price would indicate a potential upside of 348.18% from the company’s previous close. Jefferies Group also issued estimates for Kadmon’s FY2021 earnings at ($2.83) EPS and FY2022 earnings at ($1.59) EPS.
A number of other brokerages have also recently issued reports on KDMN. Zacks Investment Research cut shares of Kadmon from a “hold” rating to a “sell” rating in a report on Wednesday, January 31st. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of Kadmon in a research note on Friday, November 17th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $10.21.
Shares of Kadmon (NYSE:KDMN) traded down $0.03 during trading hours on Tuesday, hitting $3.57. 769,711 shares of the stock traded hands, compared to its average volume of 1,307,307. Kadmon has a 12 month low of $2.05 and a 12 month high of $5.86. The firm has a market cap of $279.97 and a PE ratio of -2.03.
Hedge funds have recently made changes to their positions in the company. Sawtooth Solutions LLC bought a new stake in Kadmon during the fourth quarter worth $799,000. Goldentree Asset Management LP raised its position in Kadmon by 673.6% during the fourth quarter. Goldentree Asset Management LP now owns 1,611,730 shares of the company’s stock worth $5,834,000 after acquiring an additional 1,403,397 shares in the last quarter. BlueCrest Capital Management Ltd bought a new stake in Kadmon during the fourth quarter worth $241,000. Geode Capital Management LLC raised its position in Kadmon by 172.4% during the fourth quarter. Geode Capital Management LLC now owns 463,844 shares of the company’s stock worth $1,679,000 after acquiring an additional 293,569 shares in the last quarter. Finally, Spark Investment Management LLC bought a new stake in Kadmon during the fourth quarter worth $868,000. 53.27% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/23/jefferies-group-raises-kadmon-kdmn-price-target-to-16-00.html.
Kadmon Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.